A Study of A-CAR028 Treatment in Subjects With Relapsed or Refractory Acute Myeloid Leukemia

This is a single-center, open-label study to evaluate the safety and efficacy of A-CAR028 in relapsed/refractory acute myeloid leukemia patients

Trial Details

NCT ID
NCT07198867
Phase
PHASE1
Sponsor
First Affiliated Hospital of Zhejiang University
Status
RECRUITING
Cancer Type
Leukemia
Interventions
  • A-CAR028
Locations (sample)
  • Hangzhou, Zhejiang, China|30.29365,120.16142

Key Eligibility Criteria

  • 18 to 75 years old at the time of signing the Informed Consent Form (ICF)
  • More than 12 weeks of expected survival
  • ECOG score 0 or 1
  • Relapsed or refractory AML

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Leukemia Trials on Trialify →